AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
insight
/
details

Pancreatic Cancer and Genomics: Revisiting Advances and Challenges

NextEdge Admin

24 Nov 2024

4 min 43 sec

The intersection of pancreatic cancer and genomics has led to significant advancements in understanding this aggressive disease. Here’s an updated look at the relationship between genomics and pancreatic cancer:

1. Genomic Alterations in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is marked by a range of genomic abnormalities:

KRAS Mutations: Nearly all PDACs (90-95%) harbor mutations in the KRAS gene, making it a hallmark driver mutation.
Tumor Suppressors:
- TP53 mutations occur in approximately 70-75% of cases.
- CDKN2A (p16) and SMAD4 are frequently inactivated, contributing to tumor progression.
Other Drivers:
- Alterations in genes like ARID1A, RNF43, and DNA repair genes (e.g., BRCA1/BRCA2, PALB2) have been observed.

2. Role of Genomics in Early Detection

Liquid Biopsies: Circulating tumor DNA (ctDNA) and tumor-derived exosomes provide opportunities for early detection of pancreatic cancer by identifying specific mutations or methylation patterns.
Polygenic Risk Scores (PRS): For individuals with familial pancreatic cancer, PRS integrates common genetic variants to assess cancer susceptibility.

3. Genomic Subtypes of PDAC

Genomic profiling has revealed distinct molecular subtypes of pancreatic cancer, aiding in personalized treatment strategies:

Classical: Characterized by epithelial-like features and a better prognosis.
Basal-like: Associated with more aggressive behavior and resistance to therapy.
Mutational Signatures:
- Mismatch repair deficiency (MMRd) and microsatellite instability (MSI) point to immunotherapy opportunities.
- Defects in homologous recombination (e.g., BRCA mutations) predict sensitivity to platinum-based chemotherapies and PARP inhibitors.

4. Implications for Treatment

Targeted Therapy: Genomic insights have paved the way for:
- KRAS G12C inhibitors (though efficacy in PDAC remains under investigation).
- Therapies targeting other KRAS mutations (e.g., G12D or G12V) are in development.
Immunotherapy:
- Although PDAC has been largely refractory to immune checkpoint inhibitors, MSI-high tumors or those with high tumor mutational burden (TMB) respond better.
Synthetic Lethality:
- PARP inhibitors like olaparib are effective in patients with BRCA or PALB2 mutations.

5. Emerging Research Areas

Organoid Models: Derived from patients, these models enable functional genomics and drug screening for personalized therapy.
Single-Cell Sequencing: This technology reveals tumor heterogeneity, immune microenvironment interactions, and resistance mechanisms.
Epigenomics: Altered DNA methylation and histone modifications are emerging as therapeutic targets.

6. Challenges and Future Directions

Tumor Heterogeneity: Intratumoral and intertumoral diversity complicates the development of universal biomarkers and therapies.
Early Detection Barriers: Reliable biomarkers for detecting pancreatic cancer at an early, treatable stage remain elusive.
Therapeutic Resistance: Genomic plasticity allows tumors to adapt and resist targeted therapies, underscoring the need for combination treatments.

Related Tags

Pancreatic Cancer

Genomics

Insight

Radiogenomics: a key component of precision cancer medicine

Top Reviews

No reviews yet

Pancreatic Cancer and Genomics: Revisiting Advances and Challenges

NextEdge Admin

24 Nov 2024

4 min 43 sec